ArticleFukushima journal of medical science2026
A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time.
Article in Fukushima journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To clarify the characteristics of children with attention deficit hyperactivity disorder (ADHD) requiring early drug therapy and changes in ADHD treatment over time, we undertook a clinical survey of ADHD children. We retrospectively classified 168 children with ADHD into groups based on the presence [Group 1, (the early treatment Group A, non-early treatment Group B)] or absence (Group 2) of ADHD drug therapy. The older age at first examination and the frequency of patients born with low birth weight in Group 1 were higher than those in Group 2. The ADHD-Rating Scale (ADHD-RS) scores for total (ADHD-RS-T) and trouble scores (TS) in Group 1 were higher than those in Group 2. All patients requiring early drug medication were diagnosed with ADHD at age 6 or older and showed significantly higher ADHD-RS hyperactivity disorder (ADHD-RS-H) and TS. Guanfacine was the main drug prescribed, being the first-line drug in 45.0% of cases. These results suggest that characteristics of patients requiring early ADHD drug medication include age 6 years or older at first examination and high ADHD-RS-H, ADHD-RS-T and TS. Furthermore, an increase in the frequency of prescriptions for guanfacine was observed as a prescription trend for ADHD medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.